According to the latest market research study by Technavio, the global epinephrine autoinjector market is expected to grow at a CAGR of close to 15% during the forecast period 2017 to 2021.
This report by Technavio provides an in-depth analysis of the global epinephrine autoinjector market regarding revenue and evolving market trends. The report also consists of a competitive vendor analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the dosage
Click here to request a free sample of this report
Global epinephrine autoinjector market by 0.30gm dosage: The global epinephrine autoinjector market by 0.30gm dosage is expected to witness the highest growth due to the rise in volume sales of generic epinephrine autoinjectors.
“The higher adoption of generic epinephrine autoinjectors is expected to maximize, once Mylan’s generic of EpiPen gets launched in the market. The gradual price hike of Mylan year wise, after the periodic exit of its leading competitors from the market, led researchers from universities and emerging companies to focus on developing an alternative to EpiPen. Windgap Medical’s Abiliject epinephrine autoinjector projected to be launched in 2018, promises of being better than EpiPen. Seeing the latest developments, the growth of the global epinephrine autoinjector market by 0.30gm dosage is assured,” says Sapna Jha, a lead analyst at Technavio for research on orthopedics and medical devices.
Global epinephrine autoinjector market by 0.15gm dosage: The global epinephrine autoinjector market by 0.15gm dosage is expected to witness high growth. The growth can be due to the expected rise in volume sales of Mylan’s low-cost generic EpiPen Jr to be launched in the US market in 2017. Children under 12 years are more prone to allergic reactions due to food pathogens, which necessitates the need of epinephrine autoinjector carriage, as children usually realize the emergency later than adults. In developed countries, such as the UK, the governments encourage the parents to train their children who are disposed to allergies.
Global epinephrine autoinjector market by 0.5gm dosage: The global epinephrine autoinjector market by 0.50gm dosage had the highest contribution from the EMEA market in 2016, and is forecasted to continue its growth during the forecast period. In the European countries, 0.50gm epinephrine is the recommended dose for adults weighing 60kgs and above. Emarade epinephrine autoinjector 0.50gm is popular in the markets of Sweden, the UK, and Germany. Higher growth is forecasted if Mylan plans to launch a 0.50gm dosed epinephrine autoinjector during the forecast period, to capture the European market.
Ask an analyst to know more about this report
The top vendors operating in the global epinephrine autoinjector market are:
- ALK-Abelló
- Impax Laboratories
- Lincoln Medical
- Mylan
The other prominent vendors in the market include Adamis Pharmaceuticals, Antares Pharma, Emerade, Hospira, Kaleo Pharma, and Teva Pharmaceutical Industries.
A more detailed analysis is available in the Technavio market research report titled, ‘Global Epinephrine Autoinjector Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Anticoagulant Market 2017-2021
- Global Pulmonary Endoscopy Devices Market 2017-2021
- Global Vagus Nerve Stimulation Market 2017-2021
To read more press releases – click here
